EVALUATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER: SYSTEMATIC REVIEW AND TRIAL LEVEL META-ANALYSIS

被引：0
|
作者：
Adunlin, G. [1 ]
Dranitsaris, G. [2 ]
机构：
[1] Virginia Commonwealth Univ, Richmond, VA USA
[2] Augmentium Pharma Consulting Inc, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1536
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN203
引用
收藏
页码：A170 / A170
页数：1
相关论文
共 50 条
  • [41] A trial-level correlation analysis of progression-free survival as a surrogate for overall survival in the immunotherapy era.
    Yekeduz, Emre
    Koksoy, Elif Berna
    Akbulut, Hakan
    Utkan, Gungor
    Urun, Yuksel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] IN ADVANCED/METASTATIC BREAST CANCER, IS PROGRESSION-FREE SURVIVAL A SURROGATE OUTCOME?
    Franca, A. C.
    Schroeder, L.
    Padilla, M.
    Meirelles, I
    Silva, A. S.
    Magliano, C.
    Santos, M.
    VALUE IN HEALTH, 2020, 23 : S477 - S478
  • [43] Impact of LGR5 in colorectal cancer on overall and progression-free survival: a systematic review and meta-analysis
    Yang, Ling
    Lin, Yan
    Liu, Zhihui
    Li, Yongqiang
    Liu, Yuanfang
    Liang, Rong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (06): : 10537 - 10543
  • [44] EFFECTS OF METFORMIN USE ON PROGRESSION-FREE AND OVERALL SURVIVAL OF GLIOBLASTOMA CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Menon, S. S.
    Yadav, N.
    Yeddala, S. P.
    Doucette, J.
    Harris, C.
    Murimi-Worstell, I. B.
    VALUE IN HEALTH, 2021, 24 : S19 - S20
  • [45] PROGRESSION-FREE SURVIVAL IS A ROBUST SURROGATE ENDPOINT OF OVERALL SURVIVAL IN IMMUNOTHERAPY TRIALS OF HEPATOCELLULAR CARCINOMA
    Cabibbo, Giuseppe
    Celsa, Ciro
    Enea, Marco
    Battaglia, Salvatore
    Rizzo, Giacomo
    Busacca, Anita
    Matranga, Domenica
    Attanasio, Massimo
    Reig, Maria
    Craxi, Antonio
    Camma, Calogero
    HEPATOLOGY, 2020, 72 : 649A - 649A
  • [46] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Manier, Salomon
    Lam, Annette
    Roccia, Tito
    Schecter, Jordan M.
    Cost, Patricia
    Pacaud, Lida
    Poirier, Abbey
    Tremblay, Gabriel
    Lan, Tommy
    Valluri, Satish
    Kumar, Shaji
    BMC CANCER, 2024, 24 (01)
  • [47] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [48] Progression-free survival is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma
    Celsa, C.
    Cabibbo, G.
    Enea, M.
    Battaglia, S.
    Rizzo, G. E. M.
    Busacca, A.
    Matranga, D.
    Attanasio, M.
    Reig, M.
    Craxi, A.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S35 - S35
  • [49] Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint
    Hurvitz, Sara A.
    CANCER TREATMENT REVIEWS, 2011, 37 (07) : 495 - 504
  • [50] Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer
    Hughes, Michael D.
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2008, 17 (05) : 487 - 495
12345